Department of Gastric Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Immunotherapy. 2020 Dec;12(18):1313-1324. doi: 10.2217/imt-2020-0007. Epub 2020 Oct 5.
This study aimed to evaluate the relationship between smoking status and efficacy of PD-1/PD-L1 inhibitors compared with conventional agents. We reviewed Phase II/III trials of PD-1/PD-L1 inhibitors that reported hazard ratio (HR) in current/former and never smoking patients. 15 qualifying trials comprising 9073 patients were eligible in this study. Compared with conventional agents, PD-1/PD-L1 inhibitors correlated with prolonged progression-free survival (HR: 0.73; 0.58-0.92) and overall survival (HR: 0.75; 0.71-0.80) in current/former smoker patients but not in never-smoker patients (HR: 1.15 and 0.86 for progression-free survival and overall survival, respectively; both p > 0.05) irrespective of cancer type, target of experimental agents and treatment strategy. There exit smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy.
本研究旨在评估与传统药物相比，吸烟状况与 PD-1/PD-L1 抑制剂疗效之间的关系。我们回顾了报告 PD-1/PD-L1 抑制剂在当前/既往和从不吸烟患者中风险比（HR）的 II/III 期试验。本研究纳入了 15 项符合条件的试验，共 9073 名患者。与传统药物相比，PD-1/PD-L1 抑制剂在当前/既往吸烟者患者中与更长的无进展生存期（HR：0.73；0.58-0.92）和总生存期（HR：0.75；0.71-0.80）相关，但在从不吸烟者患者中则不相关（HR：分别为 1.15 和 0.86 的无进展生存期和总生存期，均 P>0.05），而与癌症类型、实验药物的靶点和治疗策略无关。抗 PD-1/PD-L1 免疫治疗存在基于吸烟状况的疗效差异。
